Therapeutic/pharmacologic approaches to urinary incontinence in older adults

Clinical Pharmacology and Therapeutics

Volumn 85, Issue 1, 2009, Pages 98-102

  DuBeau, C E ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; AMITRIPTYLINE; ANTIHISTAMINIC AGENT; ATROPINE PLUS DIPHENOXYLATE; CHOLINERGIC RECEPTOR BLOCKING AGENT; DARIFENACIN; DICYCLOVERINE; DIHYDROPYRIDINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DISOPYRAMIDE; ESTROGEN; FESOTERODINE; GABAPENTIN; GLITAZONE DERIVATIVE; HYPNOTIC SEDATIVE AGENT; LOOP DIURETIC AGENT; MUSCARINIC RECEPTOR BLOCKING AGENT; NARCOTIC ANALGESIC AGENT; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OXYBUTYNIN; PHENYLPROPANOLAMINE; PREGABALIN; SOLIFENACIN; TOLTERODINE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIHEXYPHENIDYL; TROSPIUM CHLORIDE; UNINDEXED DRUG;

ADULT; ANTICHOLINERGIC EFFECT; BLADDER; BLADDER CONTRACTION; CONSTIPATION; COUGHING; DELIRIUM; DRUG EFFECT; DRUG SAFETY; DRUG WITHDRAWAL; FECES IMPACTION; FOOT EDEMA; HUMAN; IMMOBILIZATION; MIXED INCONTINENCE; NOCTURIA; OBSTRUCTIVE UROPATHY; OVERACTIVE BLADDER; POLYURIA; PRIORITY JOURNAL; REVIEW; SEDATION; SIDE EFFECT; STOMACH EMPTYING; STRESS INCONTINENCE; TONIC IMMOBILITY; UNSPECIFIED SIDE EFFECT; URETHRA; URGE INCONTINENCE; URINE INCONTINENCE; URINE RETENTION; XEROSTOMIA;

AGED; AGING; ANTIMUTAGENIC AGENTS; BEHAVIOR THERAPY; DRUG INTERACTIONS; GERIATRICS; HUMANS; URINARY INCONTINENCE;

EID: 57749179721     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2008.230     Document Type: Review

References (39)

1. Ruby, C., Hanlon, J.T., Fillenbaum, G.G., Pieper, C.F., Branch, L.G. & Bump, R.C. Medication use and control of urination among community-dwelling older adults. J. Aging Health 17, 661-674 (2005).
2. Resnick, N.M. & Yalla, S.V. Detrusor hyperactivity with impaired contractile function. An unrecognized but common cause of incontinence in elderly patients. JAMA 257, 3076-3081 (1987).
3. Pfisterer, M.H., Griffiths, D.J., Schaefer, W. & Resnick, N.M. The effect of age on lower urinary tract function: a study in women. J. Am. Geriatr. Soc. 54, 405-412 (2006).
4. Resnick, N.M. & Yalla, S.V. Age and the lower urinary tract: what is normal? Neurourol. Urodyn. 14, 577-579 (1995).
5. Taylor, J.A. 3rd. & Kuchel, G.A. Detrusor underactivity: clinical features and pathogenesis of an underdiagnosed geriatric condition. J. Am. Geriatr. Soc. 54, 1920-1932 (2006).
6. Elbadawi, A., Yalla, S.V. & Resnick, N.M. Structural basis of geriatric voiding dysfunction. I. Methods of a prospective ultrastructural/ urodynamic study and an overview of the findings. J. Urol. 150, 1650-1656 (1993).
7. Elbadawi, A., Hailemariam, S., Yalla, S.V. & Resnick, N.M. Structural basis of geriatric voiding dysfunction. VI. Validation and update of diagnostic criteria in 71 detrusor biopsies. J. Urol. 157, 1802-1813 (1997).
8. Trowbridge, E.R., Wei, J.T., Fenner, D.E., Ashton-Miller, J.A. & Delancey, J.O. Effects of aging on lower urinary tract and pelvic floor function in nulliparous women. Obstet. Gynecol. 109, 715-720 (2007).
9. Verelst, M., Maltau, J.M. & Ørbo, A. Computerised morphometric study of the paraurethral tissue in young and elderly women. Neurourol. Urodyn. 21, 529-533 (2002).
10. Siracusano, S. et al. Application of ultrasound contrast agents for the characterization of female urethral vascularization in healthy pre- and postmenopausal volunteers: preliminary report. Eur. Urol. 50, 1316-1322 (2006).
11. Hendrix, S.L. et al. Effects of estrogen with and without progestin on urinary incontinence. JAMA 293, 935-948 (2005).
12. Perucchini, D., DeLancey, J.O., Ashton-Miller, J.A., Peschers, U. & Kataria, T. Age effects on urethral striated muscle. I. Changes in number and diameter of striated muscle fibers in the ventral urethra. Am. J. Obstet. Gynecol. 186, 351-355 (2002).
13. Clobes, A., DeLancey, J.O. & Morgan, D.M. Urethral circular smooth muscle in young and old women. Am. J. Obstet. Gynecol. 198, 587.e1-e5 (2008).
14. Rother, P., Löffler, S., Dorschner, W., Reibiger, I. & Bengs, T. Anatomic basis of micturition and urinary continence. Muscle systems in urinary bladder neck during ageing. Surg. Radiol. Anat. 18, 173-177 (1996).
15. Bump, R., Norton, P., Zinner, N. & Yalcin, I. Duloxetine Urinary Incontinence Study Group. Mixed urinary incontinence symptoms: urodynamic findings, incontinence severity, and treatment response. Obstet. Gynecol. 102, 76-83 (2003).
16. Finney, S., Andersson, K., Gillespie, J. & Stewart, L. Antimuscarinic drugs in detrusor overactivity and the overactive bladder syndrome: motor or sensory actions? BJU Int. 98, 503-507 (2006).
17. Schwartz, J.B. & Abernethy, D.R. Aging and medications: past, present, future. Clin. Pharmacol. Ther. 85, this issue.
18. Rochon, P.A. et al. Age- and gender-related use of low-dose drug therapy: the need to manufacture low-dose therapy and evaluate the minimum effective dose. J. Am. Geriatr. Soc. 47, 954-959 (1999).
19. Bemelmans, B., Kiemeney, L. & Debruyne, F. Low-dose oxybutynin for the treatment of urge incontinence: good efficacy and few side effects. Eur. Urol. 37, 709-713 (2000).
20. Layton, D., Pearce, G.L. & Shakir, S.A. Safety profile of tolterodine as used in general practice in England: results of prescription-event monitoring. Drug Saf. 24, 703-713 (2001).
21. Lackner, T., Wyman, J., McCarthy, T., Monigold, M. & Davey, C. Randomized, placebo-controlled trial of the cognitive effect, safety, and tolerability of oral extended-release oxybutynin in cognitively impaired nursing home residents with urge urinary incontinence. J. Am. Geriatr. Soc. 56, 862-870 (2008).
22. Lipton, R., Kolodner, K. & Wesnes, K. Assessment of cognitive function of the elderly population: effects of darifenacin. J. Urol. 173, 493-498 (2005).
23. Kay, G. et al. Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects. Eur. Urol. 50, 317-326 (2006).
24. Colucci, V.J. & Rivey, M.P. Tolterodine-warfarin drug interaction. Ann. Pharmacother. 33, 1173-1176 (1999).
25. Hashimoto, M., Imamura, T., Tanimukai, S., Kazui, H. & Mori, E. Urinary incontinence: an unrecognised adverse effect with donepezil. Lancet 356, 568 (2000).
26. Siegler, E. & Reidenberg, M. Treatment of urinary incontinence with anticholinergics in patients taking cholinesterase inhibitors for dementia. Clin. Pharmacol. Ther. 75, 484-488 (2004).
27. Shamliyan, T.A., Kane, R.L., Wyman, J. & Wilt, T.J. Systematic review: randomized, controlled trials of nonsurgical treatments for urinary incontinence in women. Ann. Intern. Med. 148, 459-473 (2008).
28. Ouslander, J.G. et al. Does oxybutynin add to the effectiveness of prompted voiding for urinary incontinence among nursing home residents? A placebo-controlled trial. J. Am. Geriatr. Soc. 43, 610-617 (1995).
29. Zorzitto, M.L., Holliday, P.J., Jewett, M.A., Herschorn, S. & Fernie, G.R. Oxybutynin chloride for geriatric urinary dysfunction: a double-blind placebo-controlled study. Age Ageing 18, 195-200 (1989).
30. Szonyi, G., Collas, D.M., Ding, Y.Y. & Malone-Lee, J.G. Oxybutynin with bladder retraining for detrusor instability in elderly people: a randomized controlled trial. Age Ageing 24, 287-291 (1995).
31. Burgio, K.L. et al. Behavioral vs drug treatment for urge urinary incontinence in older women: a randomized controlled trial. JAMA. 280, 1995-2000 (1998).
32. Michel, M.C., Schneider, T., Krege, S. & Goepel, M. Does gender or age affect the efficacy and safety of tolterodine? J. Urol. 168, 1027-1031 (2002).
33. Zinner, N.R., Mattiasson, A. & Stanton, S.L. Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients. J. Am. Geriatr. Soc. 50, 799-807 (2002).
34. Ouslander, J.G., Maloney, C., Grasela, T.H., Rogers, L. & Walawander, C.A. Implementation of a nursing home urinary incontinence management program with and without tolterodine. J. Am. Med. Dir. Assoc. 2, 207-214 (2001).
35. Malone-Lee, J., Shaffu, B., Anand, C. & Powell, C. Tolterodine: superior tolerability than and comparable efficacy to oxybutynin in individuals 50 years old or older with overactive bladder: a randomized controlled trial. J. Urol. 165, 1452-1456 (2001).
36. Wagg, A., Wyndaele, J.J. & Sieber, P. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis. Am. J. Geriatr. Pharmacother. 4, 14-24 (2006).
37. Chapple, C., DuBeau, C., Ebinger, U., Rekeda, L. & Viegas, A. Darifenacin treatment of patients > or = 65 years with overactive bladder: results of a randomized, controlled, 12-week trial. Curr. Med. Res. Opin. 23, 2347-2358 (2007).
38. Chapple, C., Khullar, V., Gabrielc, Z. & Dooley, J. The effects of antimuscarinictreatments in overactive bladder: a systematic review and meta-analysis. Eur. Urol. 48, 5-26 (2005).
39. Andersson, K. LUTS treatment: future treatment options. Neurourol. Urodyn. 26 (6 suppl.),934-947 (2007).